专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4361634A2 METHODS FOR TREATING AND MONITORING THE STATUS OF CANCER 审中-实审
公开(公告)号：EP4361634A2
公开(公告)日：2024-05-01
申请号：EP23210443.0
申请日：2013-03-19
申请人： Stemline Therapeutics, Inc.
发明人： CIRRITO, Thomas P. , BERGSTEIN, Ivan , BROOKS, Christopher
IPC分类号： G01N33/574
CPC分类号： G01N33/57407 , G01N2800/5220130101 , A61K38/1793 , A61K38/45 , C12N9/12 , C12Y207/10001 , A61P25/00 , A61P35/00 , A61P37/04
摘要： Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13Rα2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13Rα2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient.

2. 发明公开

EP2849772A4 CANCER STEM CELL TARGETED CANCER VACCINES 审中-公开
标题翻译： GEGEN KREBSSTAMMZELLEN GERICHTETE TUMORIMPFSTOFFE
公开(公告)号：EP2849772A4
公开(公告)日：2016-03-02
申请号：EP13790444
申请日：2013-05-15
申请人： STEMLINE THERAPEUTICS INC
发明人： CIRRITO THOMAS P , BERGSTEIN IVAN , BROOKS CHRISTOPHER
IPC分类号： A61K38/00
CPC分类号： A61K39/0011 , A61K31/437 , A61K38/164 , A61K38/1761 , A61K38/193 , A61K38/2013 , A61K38/2086 , A61K38/21 , A61K38/30 , A61K38/45 , A61K2039/55511 , A61K2039/55522 , A61K2039/572 , C07K14/33 , C07K14/4747 , C07K14/5437 , C12N9/12 , C12Y207/10001 , A61K2300/00
摘要： Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.
摘要翻译：本文提供了癌症干细胞靶向癌症疫苗以及用于治疗和接种疫苗的方法。本文还包含施用癌症干细胞靶向癌症疫苗的方案，包括肽，组合物，免疫调节剂和乳化剂的方案。还提供了要给予方案的患者人群以及方案的剂量，时间表，给药途径。

3. 发明授权

EP3912634B1 CANCER STEM CELL TARGETED CANCER VACCINES 有权
公开(公告)号：EP3912634B1
公开(公告)日：2023-10-04
申请号：EP21162077.8
申请日：2013-05-15
发明人： CIRRITO, Thomas, P. , BERGSTEIN, Ivan , BROOKS, Christopher
IPC分类号： A61K38/00 , A61K31/437 , A61K38/20 , A61K38/30 , A61K39/00 , A61K35/00 , A61P37/04 , A61P43/00 , A61K38/17 , A61K38/21 , A61P35/00

4. 发明公开

EP2526970A1 Monitoring cancer stem cells 审中-公开
标题翻译：监测癌症干细胞
公开(公告)号：EP2526970A1
公开(公告)日：2012-11-28
申请号：EP12169758.5
申请日：2007-09-07
申请人： Stemline Therapeutics, Inc.
发明人： Cirrito, Thomas , Bergstein, Ivan
IPC分类号： A61K39/395 , A61K31/70 , C12Q1/00 , C12Q1/68 , C07H21/04 , C07K16/28 , G01N33/574 , G01N33/50
CPC分类号： G01N33/574 , G01N33/5073 , G01N33/57492 , G01N2800/52
摘要： The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.
摘要翻译：本发明涉及监测进行癌症治疗的患者中的癌症干细胞以确定癌症治疗是否是有效的癌症治疗的方法。本发明涉及用于在癌症治疗患者之前，期间和/或之后监测癌症干细胞量的方法。特别地，所述方法提供了通过体内成像测量例如从患者获得的样品中和/或ii）患者中癌症干细胞i）的量的方法。在癌症治疗方案之前，期间或之后的不同时间点。随着时间的推移，癌症干细胞数量的变化允许医生判断治疗方案的有效性，然后决定如果需要继续，改变或停止治疗方案。本发明还提供用于在癌症治疗患者之前，期间和/或之后监测癌症干细胞的试剂盒。本发明还提供了治疗癌症的方法，其中此类方法包括使用稳定或减少患者体内或来自患者的癌症干细胞量的治疗剂。

5. 发明公开

EP2081590A4 CANCER STEM CELL-TARGETED CANCER THERAPY 审中-公开
标题翻译： GEGEN KREBSSTAMMZELLEN GERICHTETE KREBSTHERAPIE
公开(公告)号：EP2081590A4
公开(公告)日：2011-12-28
申请号：EP07837839
申请日：2007-09-07
申请人： STEMLINE THERAPEUTICS INC
发明人： CIRRITO THOMAS P , BERGSTEIN IVAN
IPC分类号： A61K39/00 , A61K31/00 , A61K39/395 , A61P35/00 , G01N33/53 , G01N33/574
CPC分类号： A61K39/00 , A61K31/00 , G01N2800/52
摘要： The invention relates to an alkylating agent for use in a method of reducing cancer stem cells in patient that has been diagnosed with cancer, wherein said patient is administered said alkylating agent at a dose less than the maximum tolerated dose (MTD), and wherein the cancer stem cell population in said patient is monitored to determine whether said agent has resulted in a reduction of cancer stem cell in said patient.
摘要翻译：本发明涉及一种用于在已诊断患有癌症的患者中减少癌症干细胞的方法中的烷化剂，其中所述患者以小于最大耐受剂量（MTD）的剂量施用所述烷化剂，并且其中监测所述患者的癌症干细胞群，以确定所述药物是否导致所述患者中的癌干细胞的减少。

6. 发明公开

EP4361634A3 METHODS FOR TREATING AND MONITORING THE STATUS OF CANCER 审中-实审
公开(公告)号：EP4361634A3
公开(公告)日：2024-06-05
申请号：EP23210443.0
申请日：2013-03-19
申请人： Stemline Therapeutics, Inc.
发明人： CIRRITO, Thomas P. , BERGSTEIN, Ivan , BROOKS, Christopher
IPC分类号： G01N33/574
CPC分类号： G01N33/57407 , G01N2800/5220130101 , A61K38/1793 , A61K38/45 , C12N9/12 , C12Y207/10001 , A61P25/00 , A61P35/00 , A61P37/04
摘要： Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13Rα2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13Rα2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient.

7. 发明公开

EP4321218A3 CANCER STEM CELL TARGETED CANCER VACCINES 审中-实审
公开(公告)号：EP4321218A3
公开(公告)日：2024-04-24
申请号：EP23193214.6
申请日：2013-05-15
申请人： Stemline Therapeutics, Inc.
发明人： CIRRITO, Thomas, P. , BERGSTEIN, Ivan , BROOKS, Christopher
IPC分类号： A61K38/00 , A61K31/437 , A61K38/17 , A61K38/20 , A61K38/21 , A61K38/30 , A61K39/00 , A61P35/00 , A61P37/04 , A61P43/00
CPC分类号： A61K38/1761 , A61K38/2013 , A61K38/2086 , A61K38/21 , A61K38/30 , A61K31/437 , A61P35/00 , A61P37/04 , A61P43/00 , A61K39/0011 , A61K39/001119 , A61K39/001122 , A61K39/00115 , A61K2039/8020180801
摘要： Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to administered, and the dosages, schedules, route of administration for the regimens.

8. 发明授权

EP3536334B1 CANCER STEM CELL TARGETED CANCER VACCINES 有权
公开(公告)号：EP3536334B1
公开(公告)日：2021-06-23
申请号：EP18213178.9
申请日：2013-05-15
发明人： CIRRITO, Thomas, P. , BERGSTEIN, Ivan , BROOKS, Christopher
IPC分类号： A61K38/00

9. 发明公开

EP2526969A1 Monitoring cancer stem cells 审中-公开
标题翻译：肿瘤干细胞的监测
公开(公告)号：EP2526969A1
公开(公告)日：2012-11-28
申请号：EP12169751.0
申请日：2007-09-07
申请人： Stemline Therapeutics, Inc.
发明人： Cirrito, Thomas , Bergstein, Ivan
IPC分类号： A61K39/395 , A61K31/70 , C12Q1/00 , C12Q1/68 , C07H21/04 , C07K16/28 , G01N33/574 , G01N33/50
CPC分类号： G01N33/574 , G01N33/5073 , G01N33/57492 , G01N2800/52
摘要： The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.

10. 发明公开

EP2081590A2 CANCER STEM CELL-TARGETED CANCER THERAPY 审中-公开
标题翻译：肿瘤干细胞引导的癌症治疗
公开(公告)号：EP2081590A2
公开(公告)日：2009-07-29
申请号：EP07837839.5
申请日：2007-09-07
申请人： Stemline Therapeutics, Inc.
发明人： CIRRITO, Thomas, P. , BERGSTEIN, Ivan
IPC分类号： A61K39/00 , A61K39/395 , G01N33/53 , G01N33/574
CPC分类号： A61K39/00 , A61K31/00 , G01N2800/52
摘要： The invention relates to an alkylating agent for use in a method of reducing cancer stem cells in patient that has been diagnosed with cancer, wherein said patient is administered said alkylating agent at a dose less than the maximum tolerated dose (MTD), and wherein the cancer stem cell population in said patient is monitored to determine whether said agent has resulted in a reduction of cancer stem cell in said patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式